Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
NCT06613854 on ClinicalTrials.gov · last registry update 2026-04-30
Recruiting now, toward 90 participants. Due to report September 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Time in Range (TIR). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 October 2024 — 2 years so far. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 90
- Started
- 2024-10-01
- Primary completion
- 2027-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time in Range (TIR)
Conditions studied
Type 2 Diabetes Mellitus (T2DM)
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.